Cell therapy (NK cells) · Kills target cells, directed at CD3 (CD3E) · developed by Celularity
Taniraleucel (CYNK-001) is an off-the-shelf allogeneic natural killer cell therapy derived from human placental hematopoietic stem cells. The CD56+ NK cells recognize and kill tumor cells and virally-infected cells by secreting perforins and granzymes. It is studied in acute myeloid leukemia, glioblastoma, and COVID-19.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05218408 | Phase 1/2 | Astrocytoma, Grade IV | Withdrawn | CELU |
| NCT04365101 | Phase 1/2 | Coronavirus | Terminated | CELU |
| NCT04489420 | Phase 1 | Astrocytoma, Grade IV | Terminated | CELU |
| NCT02781467 | Phase 1 | Leukemia, Myeloid, Acute | Terminated | CELU |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
ARDSCoronaviridae InfectionsCoronavirusCoronavirus InfectionImmunologic DiseaseLeukemia, Myeloid, AcuteLung DiseasesNidovirales InfectionsPneumoniaPneumonia, ViralRespiratory Tract DiseaseRespiratory Tract InfectionsRNA Virus InfectionsSevere Acute Respiratory Syndrome Coronavirus 2
Updated Oct 3, 2026. Something wrong or missing? Report it on the CELU page.
See CELU's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
CELU catalysts and pipeline →